Lupin gets US FDA tentative nod for oxcarbazepine ER tablets
The drug is the generic equivalent of Supernus Pharmaceuticals’ Oxtellar XR and is used to treat partial-onset seizures in patients aged six and above. On…
Latest News
Nazara Technologies acquires Sachin Tendulkar-backed Smaaash for ₹126 crore
According to the announcement, the deal was part of a court-approved resolution plan under the Insolvency and Bankruptcy Code and signals Nazara’s expansion into the…
Hindustan Copper, RITES sign MoU to jointly pursue critical mineral mining projects
On Friday (June 7), shares of Hindustan Copper Ltd ended at ₹255.95, up by ₹1.90, or 0.75%, on the BSE.
Infosys receives closure from GST Intelligence on ₹32,403 crore pre-show cause notice
On Friday (June 6), shares of Infosys Ltd ended at ₹1,564.05, up by ₹9.70, or 0.62%, on the BSE.
GRSE signs MoUs in Sweden and Denmark to boost marine systems, enter expedition cruise segment
On Friday (June 6), shares of Garden Reach Shipbuilders and Engineers Ltd ended at ₹3,246.90, down by ₹159.75, or 4.69%, on the BSE.
Mahindra & Mahindra’s May sales rise 17%, production up 28% YoY
Mahindra & Mahindra reported a 17% rise in total sales and a 28% increase in production in May 2025, though exports dropped year-on-year, according to…
Infra major L&T to raise ₹500 crore via ESG bonds
Larsen & Toubro (L&T) has announced a ₹500 crore ESG bond issuance deal, becoming the first Indian corporate to do so under SEBI’s newly introduced…
MCX gets SEBI greenlight to launch electricity derivatives
India’s largest commodity exchange, MCX, has received SEBI approval to launch electricity derivatives, offering power firms and large consumers a regulated tool to hedge price…
FIIs, DIIs turn net buyers on Friday as RBI rate cut sparks market rally
Post Content
Tesla’s $380 billion wipeout marks biggest 2025 loss among top companies
Tesla is the worst-performing large-cap stock this year due to declining EV demand, Elon Musk’s political controversies, and a feud with US President Trump.